News|Articles|October 22, 2026

ESMO 2026: The Presentations That May Transform The Lung Cancer Paradigm

Fact checked by: Tim Cortese

ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in the lung cancer field.

At the European Society for Medical Oncology (ESMO) Congress 2026, expert researchers and clinicians from around the world will gather in Madrid, Spain, to share critical updates in the management of different solid tumors and other malignancies. Amidst a comprehensive program, this year’s meeting will exhibit several late-breaking abstracts and rapid oral sessions dedicated to key clinical trial data across the lung cancer paradigm.

Related to this article

October 22nd, 2026

From KEYNOTE-B49 to Novel ADCs: Breast Cancer Trials to Watch at ESMO 2026

Experts preview 6 breast cancer trials to watch at ESMO 2026, including KEYNOTE-B49, evERA, DESTINY-Breast11, SWITCH, PANKU-Breast01, and VIKTORIA-1.

Detailed anatomical illustration of the head and neck | Image Credit: © Lemdah - stock.adobe.com

October 21st, 2026

Which Head and Neck Cancer Data Should You Watch For at ESMO 2026?

An expert highlights OrigAMI-4, iza-bren plus pembrolizumab, GORTEC IDEAL, and HexAgon-HN ahead of the ESMO Congress 2026.

At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.

October 20th, 2026

Monitoring Anemia and Optimizing Regimen Selection in Resectable NSCLC

At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.

Pope Leo XIV’s lung adenocarcinoma diagnosis may increase awareness and combat stigma surrounding lung cancer screening.

October 22nd, 2026

What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism

Pope Leo XIV’s lung adenocarcinoma diagnosis may increase awareness and combat stigma surrounding lung cancer screening.

Intismeran autogene plus pembrolizumab cut the risk of recurrence or death by 42% vs pembrolizumab alone in resected stage IIB-IV melanoma.

October 22nd, 2026

Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma

Intismeran autogene plus pembrolizumab cut the risk of recurrence or death by 42% vs pembrolizumab alone in resected stage IIB-IV melanoma.

Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection.

October 22nd, 2026

Rethinking Patient Selection Strategy for Phase 1 Breast Cancer Trials

Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection.

October 22nd, 2026

FDA Accepts SonoClear System 510(k) Submission for Brain Tumor Resection Imaging

The acoustic coupling fluid is under substantive FDA review after a pivotal study of 44 patients reported improved ultrasound image quality during glioma surgery.

Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.

October 22nd, 2026

Sunvozertinib Now Available in US for EGFR Exon 20+ NSCLC

Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.